RSSBack

9 November 2007

Technology Strategy Board Autumn collaborative R&D competition

 

On 8th November 2007 the Technology Strategy Board announced a new competition for proposals for collaborative research and development, representing a Government investment in innovation of around £100m.

Submissions are being invited in eight technology areas, phased as follows:

Phase 1 Phase 2 Phase 3
Opens 8 November 2007

Closes 14 February 2008		 Opens 19 December 2007

Closes 27 March 2008		 Opens 30 January 2008

Closes 8 May 2008
Materials for energy;

High value manufacturing;

Cell therapy;		 Low carbon energy technologies;

Advanced lighting, lasers and displays;

Technologies for health;		 Gathering data in complex environments;

Creative industries;

The competition is designed to generate innovative proposals in which the business and research communities collaborate on research and technology projects to deliver successful new products and services.

Proposals with potential applications across several business sectors, which build on links between academic and business research and which involve SMEs are especially welcome. Ideally, at least one partner with defined end-user needs should also be included.

Phase 1 areas

Materials for Energy

The Technology Strategy Board and the Engineering and Physical Sciences Research Council have allocated an indicative amount of £12M to fund highly innovative collaborative research proposals in Materials for Energy. Funding is available for industry-led collaborative projects across a range of Technology Readiness Levels, from basic research to applied research and development in materials technologies that will enable the UK to rapidly meet the urgent and difficult challenges posed within the global Energy Sector.

High Value Manufacturing

The Technology Strategy Board has allocated an indicative amount of £23 million to fund highly innovative collaborative research proposals in High Value Manufacturing. Modern definitions of manufacturing tend towards one that includes all life cycle activities. It is therefore recognised that manufacturing today is concerned with the entire process from market assessment, through product design, to manufacture, support and service delivery. In addition, future manufacturing technologies must address environmental concerns, including manufacturing processes, the impact of the product in service and the responsibility for the disposal or recycling of the asset.

Cell Therapy

The Technology Strategy Board has allocated an indicative amount of £10 million to fund highly innovative collaborative research proposals in Cell Therapy. Regenerative medicine is in the vanguard of 21st century healthcare and it is this rapidly growing field of biomedicine that will revolutionize health care treatment. The worldwide market is conservatively estimated to be $500 billion by 2010. Derived from the fields of tissue engineering, tissue science, biology, biochemistry, physics, chemistry, applied engineering and other fields, regenerative medicine is the first truly interdisciplinary field that utilizes and brings together nearly every field in science. This field holds the realistic promise of regenerating damaged tissues and organs in vivo through reparative techniques that stimulate previously irreparable organs into healing themselves.

More information can be found on the Technology Strategy Board's website or on +44 (0)1355 272 155.


Back to top